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To determine the effectiveness of annual gynaecological screening (pelvic examination, transvaginal ultrasound, and CA-125), a
prospective cohort study of women at high risk for hereditary ovarian cancer was conducted. Women were offered DNA analysis
followed by either annual screening or prophylactic bilateral salpingo-oophorectomy (BSO). Study population consisted of 512 high-
risk women (median follow-up 2.07 years, range 0–9.4 years): 265 women (52%) had a BRCA mutation. Persisting abnormalities
indicated diagnostic surgery in 24 women resulting in one primary ovarian cancer FIGO stage IIIc was found. The effectiveness of
screening was studied by calculating the probability of finding ovarian cancers in the BRCA-1 and BRCA-2 carrier group and comparing
this to the identified number of ovarian cancers. The number of ovarian cancer patients found at surveillance was in accordance with
the predicted number of ovarian cancers. A total number of 169 women underwent prophylactic BSO: one ovarian cancer stage IIb
was found. In conclusion, the surveillance programme for hereditary ovarian cancer does identify patients with ovarian cancer but is
very inefficient considering the high number of surveillance visits and the advanced stage of ovarian cancer in the identified patient. For
prevention of advanced stage ovarian cancer, prophylactic BSO from age 35–40 years is a more efficient alternative.
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During the past two decades hereditary cancer has attracted
a great deal of interest. Overall, the majority of cancers is
sporadic, for example, only 5–10% of the ovarian cancers are
hereditary (Garber and Offit, 2005). In general there is a suspicion
of hereditary cancer when more than one primary tumour
in the same patient is present, several first or second-degree
relatives have cancer and/or cancer developed at an extremely
early age.
In 1994 and 1995, mutations in the BRCA-1 and BRCA-2 gene
were identified as a cause of hereditary breast and ovarian cancer
(Scully et al, 1996; King et al, 2003). The lifetime risk of carriers for
developing ovarian cancer is high, 35–60% for BRCA-1 mutation
carriers and 10–20% for BRCA-2 mutation carriers, in contrast to
the 1.8% lifetime risk of the general population (Ford et al, 1995;
Antoniou et al, 2003). BRCA mutation carriers are also at risk for
fallopian tube and primary peritoneal cancer, which usually
presents with similar clinical features as ovarian cancer. Moreover,
carriers have a 60–85% lifetime risk of developing breast cancer
(Ford et al, 1995; Antoniou et al, 2003). Incidence rates for breast
and ovarian cancer in BRCA mutation carriers have been estimated
by Antoniou et al (2003).
BRCA-1 and BRCA-2 mutation carriers often participate in a
surveillance programme for early detection of ovarian cancer
consisting of annual pelvic examination and transvaginal
ultrasound (TVU) combined with serum CA-125 assessment.
As the prognosis of ovarian cancer is poor and the efficacy
of this surveillance method has not been proven, prophylactic
bilateral oophorectomy seems to be an attractive alternative.
Since the discovery of an association between a BRCA mutation
and the development of fallopian tube cancer, bilateral oophor-
ectomy has been extended to bilateral salpingo-oophorectomy
(BSO) (Zweemer et al, 2000; Olivier et al, 2004). Bilateral
salpingo-oophorectomy (BSO) appeared to reduce not only the
risk of ovarian cancer by up to 96%, but also the risk of breast
cancer in pre-menopausal women by approximately 50% (Kauff
et al, 2002; Rebbeck et al, 2002; Calderon-Margalit and Paltiel,
2004). Furthermore, Madalinska et al (2005) found no difference in
quality-of-life between women who underwent prophylactic BSO
and women who chose for periodic screening for ovarian cancer
although women after prophylactic BSO had fewer concerns about
developing breast and ovarian cancer. Whether or not to continue
the surveillance after BSO, because of the remaining risk of
primary peritoneal cancer, is subject to discussion.
The aim of this study is to evaluate the efficacy of surveillance
for hereditary ovarian cancer at the Family Cancer Clinic at the
tertiary referral centre of the Radboud University Nijmegen
Medical Centre, The Netherlands.
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sMATERIALS AND METHODS
Study population
A total number of 512 women enrolled in the surveillance
programme for hereditary ovarian cancer from January 1995 until
January 2005 at the Family Cancer Clinic of the Radboud
University Nijmegen Medical Centre, The Netherlands. Between
1995 and 1999 women enrolled in the surveillance programme
through self-reference, reference by the department of human
genetics, the general practitioner or other specialists. After 1999,
women were first counselled at the department of human genetics
and referred to the gynaecologist when indicated. Criteria for
ovarian surveillance by the gynaecologist are described in Table 1.
DNA testing was offered when a BRCA mutation was suspected
based on criteria of the department of human genetics.
Primary surveillance was started at the age of 35 or 5 years
earlier than the youngest family member with ovarian cancer.
When a mutation was found in a hereditary breast and ovarian
cancer family during the surveillance programme, all family
members who did not carry the mutation were excluded from
the surveillance program.
At primary surveillance, information on vital status, age of
menarche, use of oral contraceptives, parity, breastfeeding,
medical history, occurrence of cancer in the family and pre- or
post-menopausal status, was collected. Furthermore, patients were
counselled on the possibilities to manage their high-risk status.
Their options consisted of annual surveillance or BSO.
Annual surveillance
Surveillance visits were performed annually and included pelvic
examination, transvaginal ultrasound (TVU) and serum CA-125
measurements. Transvaginal ultrasound (TVU) was abnormal in
case of the following morphological abnormalities: multiple cysts,
cyst with thick septa, papillary projection, irregular patterns or a
variety in sonoluency. Cutoff value for CA-125 was 35Uml
 1.I n
case of an abnormal pelvic examination and/or TVU and/or CA-
125, revision after 3 months was advised, unless the findings were
highly suspicious for a malignancy in which case diagnostic
surgery was performed. Initially, only the abnormal surveillance
test was repeated. The other surveillance tests were repeated when
the abnormal finding persisted and a diagnostic laparoscopy was
considered. When diagnostic laparoscopy was unremarkable or
only one ovary and/or tube was removed, the patient returned to
the surveillance programme. Occasionally, TVU was performed
without routine measurement of CA-125 and/or pelvic examina-
tion because the woman had recently visited her own gynaecologist
at the referring hospital.
Prophylactic bilateral salpingo-oophorectomy (BSO)
At primary counselling, patients were informed about the possible
advantages (reduction of the risk of ovarian and breast cancer) and
disadvantages (surgery, premature menopause, residual risk of
peritoneal cancer) of a BSO and about the technical aspects
(anaesthesia, risk of conversion into laparotomy). Patients who
preferred BSO underwent laparoscopy and the ovaries as well as
the fallopian tubes were removed. Hysterectomy was not part of
the standard operation. All removed ovaries and tubes were
separately histopathologically examined: a small piece of each
ovary was frozen for further analysis in the future, macroscopic
investigation for abnormalities and transverse sectioning of the
ovary and fallopian tubes was performed. The tissue sections were
formalin-fixed and paraffin-embedded. Standard 4mm thick
haematoxylin and eosin-stained sections were used for histo-
pathological examination.
After prophylactic BSO, women underwent follow-up for several
years with annual CA-125 measurement. Since 2002 only one
follow-up visit was performed and when no abnormalities were
found the women were excluded from further control.
To check for the development of peritoneal cancer in any of the
women who participated in our study the national pathology
database (PALGA), in which all pathological diagnoses in the
Netherlands are collected, was consulted for the existence of
pathology reports with the diagnosis of ovarian, fallopian tube and
peritoneal cancer of each woman until the first of January 2005.
Statistical analysis
Data analysis was performed using SPSS 12.0.1 software packet
(SPSS Inc. Chicago) and Microsoft Excel. The calculated incidence
rates were based on incidence rates found by Antoniou et al
(2003). Differences between characteristics were tested two-sided
with the w
2-test with Yates’ correction for small numbers, when
necessary. Differences in continuous characteristics, like age, were
tested with the t-test. P-valuesp0.05 were considered significant.
RESULTS
Patient characteristics
The median age of all 512 women at enroliment in the surveillance
programme was 42 years (range 20–75 years). An overview of the
Table 1 Criteria for referral to the gynaecologist for ovarian surveillance
(Vasen et al, 1998; Sutcliffe et al, 2000)
Criteria for referral
K Women with a proven BRCA-1 and/or a BRCA-2 mutation.
K Women from a family with a proven BRCA mutation but who are not (yet)
tested for a mutation.
K Women with first- or second-degree relatives with breast cancer before the
age of 50, and ovarian cancer in the family.
K Two first-degree relatives or one first-degree and one second-degree relative
with ovarian cancer, independent of age.
Table 2 Patient characteristics of 512 women at primary surveillance
Study population
Median age 42 years Range 20–75 years
Median follow-up 2.07 years Range 0–9.4 years
Type mutation no. (%) Number Percentage
BRCA-1 180 (34.2%)
BRCA-2 84 (16%)
BRCA-1 and BRCA-2 1 (0.2%)
No mutation
a 99 (19.1%)
Unknown 6 (1.5%)
Not tested 142 (27.3%)
Menopausal state 502
Pre-menopausal 372 (72.7%)
Post-menopausal 130 (25.4%)
Missing 10 (1.9%)
Previous oral contraceptive use 199 (38.8%)
Previous pregnancy 403 (78.7%)
Previous breast cancer 165 (32.1%)
Previous abdominal surgery
b 171 (33.4%)
Unknown 10 (1.9%)
aThese patients underwent DNA testing during the surveillance programme and
appeared to have no mutation.
bAbdominal surgery: for example, caesarean
section(s), abdominal hysterectomy, salpingo-oophorectomy and appendectomy or
other abdominal operations.
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spatient characteristics is given in Table 2. Ten women died during
the surveillance period: seven died of breast cancer metastases, two
died of massive lung embolism and in one case the cause of death
was unknown. No patients died of ovarian cancer or primary
peritoneal cancer.
Ovarian cancer surveillance
A total of 1621 surveillance visits were performed. The median
number of surveillance visits per patient was two (range 1–13
visits) and the median follow-up was 2.07 years (range 0–9.4
years) in a total follow-up of 1029 women-years. See Table 3 for the
results of pelvic examination, TVU and CA-125 measurements. In
the majority of initial abnormal diagnostic tests (343/378¼90.7%),
the abnormality could no longer be observed within 3–6 months.
Diagnostic laparoscopy due to abnormal findings at pelvic
examination and/or TVU and/or CA-125 was indicated in 24
women. The median time between first surveillance and the
diagnostic laparoscopy was 5 months (range 4–98 months). See
Table 4 for an overview of the indications and outcome of these 24
diagnostic laparoscopies. Diagnostic laparoscopy was never
indicated solely on a single abnormal pelvic examination (normal
TVU and CA-125). The diagnostic laparoscopy procedure was
converted to laparotomy in three cases (12.5%) owing to the size of
the enlarged ovaries. One FIGO stage IIIc ovarian cancer was
diagnosed during diagnostic surgery in a 52-year-old carrier of a
BRCA-1 mutation with a history of breast cancer.
During the surveillance programme 99 women out of the 364
women who underwent DNA analysis appeared not to carry a
BRCA mutation. Thirteen of these women were members of a
family in which a mutation was detected, 86 women were member
of a family with no mutation but were at increased risk of ovarian
cancer based on the family history. In retrospect, the 13 women
without a mutation from a proven mutation family were not at
high risk of ovarian cancer. These 99 women underwent 425
surveillance visits, seven had a prophylactic BSO and six had a
diagnostic laparoscopy.
Incidence rates of the BRCA-1 and BRCA-2 mutation carriers
based on incidence rates found by Antoniou et al (2003) are shown
in Table 5. In our group of BRCA-1 mutation carriers we calculated
a 92% incidence rate in 248 woman-years. According to these
Table 3 Overview of initially abnormal findings at surveillance and
follow-up
Surveillance findings
Number of
abnormal
findings
Number of
abnormalities
that disappeared
after 3–6 months
Pelvic examination (n¼1372) 11 (2%) 5 (45%)
CA-125 (Uml
 1)( n¼1278) 50 (4%) 43 (86%)
Transvaginal ultrasound (n¼1493) 317 (21%) 295 (93%)
Total (n¼4143) 378 (9 %) 343 (91%)
91% in bold emphasizes the percentage.
Table 4 Overview of indications and results of diagnostic laparoscopies in 24 women
Abnormal finding(s) which led to diagnostic surgery No of diagnostic laparoscopies Outcome
Abnormal pelvic examination 0 0
Abnormal CA-125 (X35Uml
 1) 1 1 – No abnormalities
Abnormal ultrasound 12 8 – Ovarian benign tumour
a
3 – No abnormalities
1 – Haemorrhagic corpus luteum
Abnormal pelvic examination and CA-125 (X35Uml
 1) 1 1 – No abnormalities
Abnormal pelvic examination and ultrasound 4 4 – Ovarian benign tumour
b
Abnormal CA-125 (X35Uml
 1) and ultrasound 5 1 – Salpingitis and paratubal cyst
1 – Metastasis of breast cancer
1 – No abnormalities
1 – Ovarian cancer FIGO IIIc
1 – Endometriosis
Abnormal pelvic examination, CA-125 (X35Uml
 1) and ultrasound 1 1 – Metastasis of breast cancer
FIGO, International Federation of Gynecology and Obstetrics.
aIn this group two patients had diagnostic laparoscopy converted to laparotomy.
bIn this group one patient had
diagnostic laparoscopy converted to laparotomy. Ovarian cancer FIGO IIIc in bold emphasizes the finding of only one ovarian cancer.
Table 5 BRCA-1 mutation carriers incidence during surveillance
Follow-up (years) Group incidence (%)
a Total group incidence (%) No surveillance visits
Age group (years) BRCA-1 BRCA-2 BRCA-1 BRCA-2 BRCA-1 BRCA-2 BRCA-1 BRCA-2
20–24 4.37 0.76 0.001 0.001 0.004 0.001 9 6
25–29 38.54 2.65 0.002 0.002 0.077 0.005 69 10
30–34 80.05 30.16 0.18 0.004 14.409 0.120 115 43
35–39 75.61 20.06 0.28 0.01 21.170 0.200 158 34
40–44 25.51 6.45 0.87 0.08 22.193 0.516 53 18
45–49 12.15 12.79 1.49 0.14 18.103 1.790 26 29
50–54 5.12 4.38 0.96 0.6 4.915 2.628 19 12
55–59 3.54 3.60 1.19 0.75 4.212 2.700 13 12
60–64 0.80 1.53 2.26 0.38 1.808 0.581 3 5
65–69 2.09 0.30 2.49 0.42 5.204 0.126 4 1
470 0.30 0.001 1
Total 248.1 82.68 92.095 8.667 470 170
aBased on incidence rates of Antoniou et al (2003).
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scalculations we predicted to find one ovarian cancer, which was
subsequently observed. In 82 woman-years of the BRCA-2
mutation carrier group a 8.7% incidence rate was calculated. In
line with these calculations, we did not find an ovarian cancer case
in this group.
Prophylactic BSO
Prophylactic BSO was chosen by 169 women (169/512¼33%). Of
these 169 women, 149 (88.1%) were carrier of a genetic mutation:
104 BRCA-1,4 4BRCA-2 and one woman was a carrier of both
mutations. Twenty women without a BRCA mutation underwent a
prophylactic BSO (seven had no mutation, the results of DNA
analyses of five women were pending, seven women were not yet
tested and in one woman the DNA status was unknown).
The median time between primary surveillance and BSO was
4 months (range 0–111 months). The median age of the women,
who chose prophylactic BSO was 45 years (range 29–70 years).
Eleven BSOs were converted to laparotomy due to intra-abdominal
adhesions and/or otherwise not being able to resect the ovaries and
tubes completely. One (0.6%) BSO was complicated by a wound
infection. Of all BSOs, one (0.6%) FIGO stage IIb ovarian cancer
was diagnosed in a 60-year-old BRCA-2 mutation carrier with a
history of breast cancer. The BSO was performed within one year
after primary surveillance.
Final histopathological examination of the other ovaries and
tubes showed one borderline malignancy, one dysplasia of the
Fallopian tube and 31 cases with benign conditions, for example,
serous cysts of the ovaries and endometriosis. All other
histopathological examinations of the ovaries and Fallopian tubes
were normal. Until the first of January 2005 no primary peritoneal
cancers were diagnosed in these women after BSO.
DISCUSSION
In this large, single-institution analysis, only two cases of ovarian
cancer were diagnosed during annual surveillance for several
years, among 512 women at high hereditary risk of ovarian cancer.
One ovarian cancer (FIGO stage IIIc) was diagnosed at diagnostic
laparoscopy after abnormal findings at the first surveillance visit in
a 52-year-old patient with a history of breast cancer and carrier of
a BRCA-1 mutation. The other ovarian cancer (FIGO stage IIb) was
diagnosed after BSO, which was intended to be prophylactic after
normal surveillance 4 months earlier, in a 60-year-old patient with
a history of breast cancer and carrier of a BRCA-2 mutation. No
interval cancers were identified.
The predicted number of ovarian cancers related to age and the
presence of a BRCA mutation was calculated, using the incidence
rates of Antoniou et al (2003). Based on these calculations the
Table 6 Overview of literature: surveillance for ovarian cancer in high-risk women
Study Oei (2006)
Stirling et al
(2005)
Meeuwissen
et al (2005)
Vasen et al
(2005)
Laframboise
et al (2002)
Scheuer et al
(2002)
Kauff et al
(2002)
Dorum et al
(1999)
Mean age of
patients in years
(range)
40 (20–75) Unknown 42 (18–77) Unknown 47 (22–70) 47.7 (24.1–79) 45.5 (35–77.7) 41 (18–77)
No. of patients 512 high-risk
women
1110 high-risk
women
383 high-risk
women
138 high-risk
women
311 high-risk
women
251 mutation
carriers
170 mutation
carriers
754 high-risk
women
No. of patients
with a mutation
180 BRCA-1 Unknown 127 BRCA-1 77 BRCA-1 26 BRCA-1 251 (distribution
unknown)
104 BRCA-1 Not tested
84 BRCA-2 25 BRCA-2 18 BRCA-2 5 BRCA-2 66 BRCA-2
1 BRCA-1
and BRCA-2
No. of surveillance
consults
1621 3701 1273 227 1555 Unknown
(89 women)
350 Unknown
No. of diagnostic
surgeries
24 29 20 36 9 10 11 Unknown
Incidence of cancer
in women
undergoing
surveillance
(FIGO stage)
1 ovarian 10 ovarian 1 breast
metastasis
6 ovarian 1 ovarian 4 ovarian 4 ovarian 16 ovarian
1 Stage IIIc 3 Stage Ic 5 Stage III Stage Ia 2 Stage 1 1 peritoneal 6 Stage I
1 Stage IIb 1 Stage IV 1 Stage II 4 Borderline
stage I
Others unknown
1 Stage IIc 1 Unstaged
1 Stage IIIb 1 peritoneal
3 Stage IIIc
1 Stage IV
Incidence of
interval cancers
0 2 2 000 0 0
No of patients
choosing for
prophylactic BSO
169 Unknown 133 97 Not performed 90 98 Not performed
Incidence of
diagnosed cancers
at prophylactic
BSO
1 ovarian 1 ovarian 1 fallopian 1 ovarian Not applicable 2 ovarian 1 peritoneal Not applicable
1 Stage IIb 1 Stage IIIa tube Stage IIc 2 Stage I
2 breast metastasis Stage Ia 2 fallopian
1 breast tube
metastasis 1 Stage I
1 Stage II
Note: All stages ordered in FIGO stage, International Federation of Gynecology and Obstetrics.
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sprobability of finding one ovarian cancer in the BRCA-1 mutation
carrier group was 92% and the probability of finding one ovarian
cancer in the BRCA-2 mutation carrier group was 8.7% (see Tables
5 and 6). Judging on these calculations the probability of finding
an ovarian cancer in the non-BRCA carriers is smaller than that for
mutation carriers.
Based on the probability calculations and the findings during
surveillance, we conclude that the surveillance programme does
identify ovarian cancer patients, but is very inefficient for two
reasons: (1) although the patient we identified at surveillance had
advanced stage disease only the detection of early-stage disease
will lead to an improvement of prognosis which is one of the
primary goals of screening. (2) The detection of one patient with
ovarian cancer requires disproportioned screening efforts in this
group of high-risk women.
The cancer rates published by Antoniou et al (2003) are based on
measurements obtained from a population that was tested for BRCA
mutations regardless of family history. The women in our study
were selected based on family history, which may have led to slightly
higher incidence rates than the rates of Antoniou et al (2003).
Other ovarian cancer surveillance publications mainly report
about patients with one affected family member (breast and/or
ovarian cancer) (Bourne et al, 1991; Dorum et al, 1999). Limited
data are available regarding women who enrolled in a study strictly
on ‘high-risk’ criteria as shown in Table 1. This complicates
comparisons between the different groups. See Table 6 for an
overview of the most recent surveillance studies of high-risk
women (TVU, CA-125 with (Dorum et al, 1999; Meeuwissen et al,
2005; Vasen et al, 2005) or without pelvic examination (Kauff
et al, 2002; Laframboise et al, 2002; Scheuer et al, 2002; Stirling
et al, 2005). Some studies report detection of advanced stage
ovarian cancer, while a disappointing low number of patients
appeared to have early stage cancer. Remarkably, only two of the
studies cited in Table 6 reported interval cancers. Conversely, in
other studies patients with a lower risk of ovarian cancer based on
the family history were faced with interval ovarian cancers (van
Nagell et al, 2000; Tailor et al, 2003). Stirling et al (2005) annually
screened 1,110 high-risk women and only found two early stage
(stage I) ovarian cancers. All other ovarian cancer patients had
advanced stage disease. Meeuwissen et al (2005) calculated the
sensitivity and specificity of this surveillance method and report a
limited sensitivity with a high number of false-positive findings.
Both groups also concluded that screening for ovarian cancer in
high-risk women is highly ineffective.
A ‘wait-and-see’ protocol was followed regarding patients with
abnormal findings during surveillance. This approach was
supported by the high percentage (490%) of abnormal findings,
which normalized within 3–6 months. Pelvic examination did not
have an additional role in detecting significant abnormalities in
our patients. In all 1372 pelvic examinations, no isolated
abnormality at pelvic examination indicated diagnostic laparo-
scopy. Apparently, pelvic examination does not have a diagnostic
role and can be omitted during surveillance.
Most of the abnormalities at surveillance concerned TVU and/or
CA-125 measurements. In 21.2% of all the TVU and 3.9% of all CA-
125 measurements abnormalities were detected (see Table 3),
probably due to the pre-menopausal status of the majority of
women in our study. These women have a variety of both
physiological (e.g. menstrual cycle) and benign conditions that can
give rise to false-positive abnormalities on TVU (e.g. follicle cysts)
or CA-125 measurements (e.g. endometriosis). This observation
may have contributed to the high incidence of normalizing
abnormalities.
In our study 69% of the carriers underwent BSO. This
percentage is slightly higher than found in previous clinical
studies, 58–60% (Kauff et al, 2002). The percentage of women
choosing BSO increases with the age of women. Young women
prefer to wait with prophylactic BSO until their family is complete.
At the end of the study period, 88 (51%) of the 171 women who
chose for screening were under the age of 40.
The observation that only one BSO patient had early-stage
ovarian cancer combined with the low incidence of ovarian cancer
in women after BSO confirms earlier reports about the effective-
ness of prophylactic BSO in preventing advanced stage ovarian
cancer. Rebbeck et al (2002) and Schwartz et al (2003) demon-
strated that prophylactic bilateral oophorectomy reduces the risk
of ovarian cancer with 85–95%. The observation of one case of
ovarian cancer in 169 BSOs is lower than that was observed in
other studies (Lu et al, 2000; Rebbeck et al, 2002; Scheuer et al,
2002). Until now BSO is the only evidence-based risk-reducing
method for women at high risk of ovarian cancer. Moreover, BSO
also reduces the risk of breast cancer in pre-menopausal women.
Therefore, we would recommend counselling for prophylactic BSO
from the age of 35–40 years in BRCA mutation carriers.
Limitations of our study include the non-randomized and
observational design. However, randomizing is ethically impos-
sible between surveillance and no surveillance. Moreover, the
calculations using the incidence rates of Antoniou et al (2003)
were very helpful in analyzing the effectiveness of surveillance. The
data from our study are a representation of daily practice and
give a true representation of this clinically relevant group.
Studies with a larger group of BRCA mutation carriers and longer
follow-up need to be performed before more definitive conclusions
can be made.
In conclusion, we report one of the largest studies in women
with a proven mutation at high risk of hereditary ovarian cancer in
a single institutional setting. This surveillance programme
identified one patient with advanced stage ovarian cancer. In
retrospect, this reflects the predicted incidence rates for high-risk
women in this age group. Apparently, this surveillance programme
does identify patients with ovarian cancer but is very inefficient
considering the high number of surveillance visits and the
advanced stage of ovarian cancer in the identified patient. For
prevention of ovarian cancer, prophylactic bilateral salpingo-
oophorectomy from age 35–40 years is a more efficient alternative.
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